April 18, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

TREAKISYM® Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma

TOKYO, Japan, April 18, 2018 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today that the combination therapy of TREAKISYM® and Rituximab ("BR Therapy") has achieved more than 50% market share for 1st line low grade non-Hodgkin lymphoma ("1st line NHL") as of March 2018, outperforming the conventional therapy, R-CHOP, according to a regular marketing survey of approximately 200 hematologists conducted by an external research firm. In the same survey, the market share of R-CHOP declined to 32%.

Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated: "We are extremely pleased that the market share of BR Therapy has surpassed 50% within just 15 months of its launch, achieving an important milestone for SymBio. BR Therapy is gaining acceptance as the new standard. To benefit patients, SymBio will do its best to soon reach 70% market share, which is our near-term target."

As BR Therapy is used overseas as standard therapy in 1st line NHL in accordance with the guidelines of NCCN and others, there were strong demands from patient groups and medical associations in Japan for early approval due to superior efficacy and safety. Since its approval in December 2016, BR Therapy has been valued by healthcare professionals and steadily replacing R-CHOP as the standard therapy.

SymBio, looking toward its second inauguration in 2020, is aiming to further enhance the value of TREAKISYM® by establishing it as the new standard therapy for 1st line NHL and achieving 80% market share by the end of 2020.

No revision to SymBio's financial forecasts for FY 2018 is anticipated due to this announcement.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

Bendamustine is a unique compound having chemical properties of both an alkylating agent[1] and a metabolic antagonist[2], and a mode of action different from other anti-cancer drugs. It is expected that bendamustine, given its unique properties, could be effective for the treatment of solid tumors as well as malignant lymphoma. A number of clinical studies of bendamustine injectables have been conducted outside of Japan to explore this potential, with clinical efficacy reported for certain solid tumors, including breast cancer, small-cell lung cancer, and soft tissue sarcoma. Furthermore, clinical studies of oral bendamustine for multiple myeloma, low-grade non-Hodgkin's lymphoma, and chronic lymphocytic leukemia have indicated favorable results with respect to both safety and tolerability of oral formulation.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August, 2016.
- TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved for manufacturing and marketing in Japan in September, 2016.
- TREAKISYM® was approved for the additional indication of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December, 2016.

TREAKISYM® has been marketed through Eisai Co., Ltd. since December, 2010.

1. An alkylating agent is a type of cytotoxic anti-cancer drug. Alkylating agents inhibit DNA replication by attaching alkyl group sites to the DNA chain.
2. A metabolic antagonist is a type of cytotoxic anti-cancer drug. Metabolic antagonists prevent DNA replication and the growth and division of tumor cells by interfering with the utilization of substances produced in the metabolic process.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio's

underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.